

Tiragolumab Biosimilar - Ultra Low Endotoxin

Product Code: ICH5078UL

More Information

Species Reactivity: Human

Target: TIGIT

Concentration: >1mg/ml

Isotype: Human IgG1

product name H2: Tiragolumab Biosimilar - Ultra Low Endotoxin

Antibodies against the same target: [Anti-Human TIGIT \(4E1.2\) In Vivo Antibody - Low Endotoxin \(ICH1219\)](#), [Anti-Mouse TIGIT \(1G9\) In Vivo Antibody - Low Endotoxin \(ICH1220\)](#), [Vibostolimab Biosimilar - Research Grade \(ICH5159\)](#), [Tamgiblimab Biosimilar - Research Grade \(ICH5279\)](#), [Belrestotug Biosimilar - Research Grade \(ICH5384\)](#), [Dargistotug Biosimilar - Research Grade \(ICH5465\)](#), [Domvanalimab Biosimilar - Research Grade \(ICH5486\)](#), [Etigilimab Biosimilar - Research Grade \(ICH5536\)](#), [Lancastotug Biosimilar - Research Grade \(ICH5623\)](#), [Ociperlimab Biosimilar - Research Grade \(ICH5722\)](#), [Ralzapastotug Biosimilar - Research Grade \(ICH5803\)](#), [Renvistobart Biosimilar - Research Grade \(ICH5816\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: Q495A1

Gene ID: 201633

Shipping Conditions: Blue ice

background: This product is an unconjugated, non-therapeutic recombinant analog of tiragolumab, a fully human IgG1 antibody directed against TIGIT (T-cell immunoreceptor

with Ig and ITIM domains). It is manufactured as a research-grade biosimilar for laboratory use only and is not the clinical drug, nor is it intended for human or veterinary use. Built around the well-characterized TIGIT target, it is intended as a defined, reproducible tool for studying TIGIT-axis biology in vitro and in preclinical settings. Typical applications include use as a positive control or benchmarking reagent in TIGIT binding and blockade assays, as a reference antibody when screening or characterizing novel anti-TIGIT candidates, and as a starting point for ADCC or antibody-engineering workflows. The material is supplied at low endotoxin levels (research grade 1 EU/mg; ultra-low 0.5 EU/mg) and is available in bulk milligram-to-gram quantities to support scale-up, assay standardization, and preclinical model work. Lot-to-lot consistency and defined format make it suitable for controls and comparability studies across long-running research programs. TIGIT (T-cell immunoreceptor with Ig and ITIM domains; also called VSIG9 or VSTM3) is a co-inhibitory receptor of the immunoglobulin superfamily expressed on activated T cells, regulatory T cells, and natural killer (NK) cells. It binds the nectin-family ligands CD155 (PVR) and, with lower affinity, CD112 (PVRL2/nectin-2), competing with the co-stimulatory receptor CD226 (DNAM-1) for these ligands. Engagement of CD155 delivers inhibitory signals through TIGIT's cytoplasmic ITIM and ITT-like motifs, dampening T-cell and NK-cell activation, cytokine production, and cytotoxicity. As an immune checkpoint, TIGIT contributes to peripheral tolerance and to immune evasion in the tumor microenvironment, making the TIGIT-CD155-CD226 axis a focus of cancer immunology research.

Other names: V-set and immunoglobulin domain-containing protein 9, V-set and transmembrane domain-containing protein 3, T-cell immunoreceptor with Ig and ITIM domains, VSIG9, VSTM3

Specificity: Detects human TIGIT. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Tiragolumab.

Purification Method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 0.1 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Bio X Cell Code: SIM0033

Suggested H1: Tiragolumab (anti-TIGIT) Biosimilar - Ultra Low Endotoxin

FAQ (Q&A):

Q: Why choose the ultra-low-endotoxin Tiragolumab biosimilar?

A: The ultra-low-endotoxin format minimises endotoxin-driven background, making it well suited to sensitive in vivo and functional studies.

Q: Can I order the Tiragolumab biosimilar in bulk?

A: Yes — it is manufactured in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: What does the Tiragolumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Tiragolumab that binds human TIGIT for research use only (RUO).